The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 26, 2022

Filed:

Aug. 21, 2019
Applicant:

G1 Therapeutics, Inc., Research Triangle Park, NC (US);

Inventors:

Jessica A. Sorrentino, Durham, NC (US);

Jay Copeland Strum, Hillsborough, NC (US);

John E. Bisi, Apex, NC (US);

Andrew Beelen, Research Triangle Park, NC (US);

Assignee:

G1 Therapeutics, Inc., Research Triangle Park, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61P 35/00 (2006.01); A61K 31/4709 (2006.01); A61K 31/517 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 31/4709 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61P 35/00 (2018.01);
Abstract

The present invention provides methods for treating a EGFR-mutant cancer in a patient by administering a selective CDK4/6 inhibitor described herein in combination or alternation with an EGFR-TKI to delay or reverse acquired resistance to previously administered EGFR-TKIs. In addition, methods for treating a EGFR-mutant cancer in a patient by administering a selective CDK4/6 inhibitor described herein in combination or alternation with an EGFR-TKI are provided wherein an intrinsically EGFR-TKI resistant EGFR-mutant cancer is sensitized to the effects of the EGFR-TKI.


Find Patent Forward Citations

Loading…